查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1835494

男性不孕症市場（按治療類型、產品類型、最終用戶和分銷管道）—2025-2032 年全球預測

Male Infertility Market by Treatment Type, Product Type, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，男性不孕症市場規模將成長至 83.3 億美元，複合年成長率為 9.30%。

主要市場統計數據
基準年2024年 40.9億美元
預計2025年 44.6億美元
預測年份：2032年 83.3億美元
複合年成長率（%） 9.30%

全面介紹影響男性不孕症治療的臨床、技術和政策方面以及多種治療環境下的行業反應

男性不孕症已從一個小眾臨床問題演變為生殖醫學、診斷學、器材工程和公共衛生政策交叉領域的多學科挑戰。隨著檢測技術的進步、對遺傳和內分泌因素的深入了解以及患者認知度的提高，男性不孕症已成為不孕症治療的核心問題。隨著臨床醫生和研究人員不斷完善診斷標準和治療方法，產業相關人員正在重新調整其產品組合，以兼顧緊急臨床需求和長期生殖健康結果。

與傳統的治療視角不同，現代實踐強調整合醫學，將精準診斷與個人化治療方案結合。輔助生殖技術的普及，以及對精液分析、基因檢測和微創手術技術的投資，正在為跨臨床學科和商業領域的合作創造機會。在這一轉變中，法律規範和付款方考量持續影響技術的採用和臨床試驗的設計，凸顯了創新者、臨床醫生和政策制定者之間策略合作的必要性。

技術進步、以患者為中心的護理模式以及診斷主導的途徑如何重塑男性不孕症的臨床實踐和商業策略

由於技術的日趨成熟、患者期望的不斷變化以及診斷和治療手段的融合，男性不孕症治療領域正在發生變化。精準診斷，例如更便捷的基因檢測和高解析度精液分析，正在重新定義診斷途徑，並促成個人化介入。同時，輔助生殖技術的不斷改進，例如卵細胞質內單一精蟲顯微注射術和靶向精子提取，正在為存在顯著男性因素問題的夫婦提供更多治療選擇。

同時，非傳統治療方法正日益普及。生活方式療法和替代療法，例如針灸、營養最佳化和系統性體重管理，正日益被納入孕前護理計劃。這種轉變反映了更廣泛的衛生系統優先事項，即更傾向於整體的、以患者為中心的模式和預防策略。在商業方面，設備的小型化、實驗室自動化程度的提高以及遠端監控數位化工具的採用，正在降低服務擴展的門檻，並鼓勵新進入者和策略合作夥伴關係的建立。總而言之，這些動態正在重塑臨床決策，並加速研究成果轉化為實踐。

評估 2025 年實施的美國關稅對生殖健康設備、診斷和治療分銷的累積營運和供應鏈影響

2025年美國關稅的推出和實施，為支持生殖健康技術的全球供應鏈帶來了顯著的摩擦，對製造商、經銷商和臨床服務提供者產生了影響。離心機、培養箱和精密顯微鏡等專用設備的進口成本增加，增加了實驗室和診所的採購複雜性，促使一些醫療保健提供者重新評估其供應商關係和庫存策略。為此，製造商和經銷商探索了本地組裝、採購多元化和價格調整等方案，以維持對必需設備的供應。

除了設備之外，關稅還可能影響用於基因檢測、荷爾蒙測定和精液分析的診斷耗材和試劑的供應和成本結構。這些壓力促使實驗室網路最佳化採購週期，投資於替代供應商的技術檢驗，並加速採用更有效率的工作流程，以減少每次檢測的耗材使用量。同時，跨境生物製藥和補​​充劑正面臨經濟轉型，這可能會影響其銷售管道策略，一些供應商優先考慮直銷和區域合作，以減輕關稅的影響。因此，相關人員正在平衡短期營運應對措施和長期策略舉措，以增強對持續貿易政策波動的抵禦能力。

以細分市場為重點的洞察，將治療方法、產品類型、臨床最終用戶和分銷策略聯繫起來，以確定開發和商業化路徑的優先順序

男性不孕症領域細分領域的動態揭示了差異化的價值促進因素，這些因素為跨治療方式、產品類型、最終用戶和通路的產品開發和市場加速策略提供了資訊。輔助生殖技術包括ICSI、IUI和IVF；生活方式和替代療法包括針灸、營養補充和體重管理；藥物療法包括抗生素療法、抗氧化療法和荷爾蒙療法；手術療法包括睪丸精子提取、精索靜脈曲張切除術和血管成形術。每個治療領域都呈現不同的臨床工作流程、報銷考量和證據生成需求，這些都會影響採用時間表。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 針對Y染色體微缺失的基因治療進展，以最佳化男性生育能力
  • 氧化壓力生物標記研究的激增將指導男性不孕症治療中的個人化抗氧化療法。
  • 男科學研究所擴大人工智慧精液分析平台的應用，以提高診斷準確性
  • 擴大以遠端醫療基礎的不孕症諮詢服務，以解決男性獲得生殖保健服務的差異
  • 發展 3D 睪丸類器官作為男性不孕症研究中新藥篩檢的預測模型
  • 增加對非荷爾蒙男性避孕藥的投資將影響睪丸調節研究

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章 男性不孕症市場（依治療類型）

  • 輔助生殖技術
    • 卵胞漿內單一精子注射
    • 人工授精
    • 體外受精
  • 生活方式和替代療法
    • 針刺
    • 營養補充
    • 體重管理
  • 藥物治療
    • 抗生素治療
    • 抗氧化療法
    • 荷爾蒙療法
  • 外科手術
    • 睪丸精子採集
    • 靜脈曲張切除術
    • 血管吻合術

9. 男性不孕症市場（依產品類型）

  • 裝置
    • 離心機
    • 培養箱
    • 顯微鏡
  • 診斷
    • 基因檢測
    • 荷爾蒙水平測試
    • 精液分析
  • 藥物
    • 抗生素
    • 抗氧化劑
    • 荷爾蒙
  • 補充
    • 胺基酸
    • 草本萃取物
    • 維他命

第 10 章 男性不孕症市場（依最終使用者）

  • 診斷中心
  • 不孕不育診所
  • 醫院
  • 研究機構

第11章 男性不孕市場（依分銷管道）

  • 直銷
  • 醫院藥房
  • 網路藥局
  • 零售藥局

第12章 男性不孕市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 男性不孕市場（依群體）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 男性不孕市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Ferring Arzneimittel AG
    • Merck KGaA
    • Bayer AG
    • Sun Pharmaceutical Industries Ltd
    • Endo International plc
    • Roche Diagnostics International AG
    • Thermo Fisher Scientific Inc
    • Cook Medical LLC
    • Hamilton Thorne Ltd
    • Vitrolife AB
Product Code: MRR-43286DA08074

The Male Infertility Market is projected to grow by USD 8.33 billion at a CAGR of 9.30% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.09 billion
Estimated Year [2025] USD 4.46 billion
Forecast Year [2032] USD 8.33 billion
CAGR (%) 9.30%

A comprehensive introduction to the evolving clinical, technological, and policy dimensions shaping male infertility care and industry response across multiple care settings

Male infertility has evolved from a niche clinical concern into a multidisciplinary challenge that intersects reproductive medicine, diagnostics, device engineering, and public health policy. Advances in laboratory techniques, a deeper understanding of genetic and endocrine contributors, and growing patient awareness have elevated male factor infertility to a central consideration in fertility pathways. As clinicians and researchers refine diagnostic criteria and therapeutic approaches, industry stakeholders are recalibrating portfolios to address both acute clinical needs and long-term reproductive health outcomes.

Transitioning from historical perspectives, contemporary practice emphasizes integrated care that combines precision diagnostics with individualized treatment plans. The surge in assisted reproductive technologies has been paralleled by investments in semen analytics, genetic testing, and minimally invasive surgical techniques, creating opportunities for collaboration across clinical disciplines and commercial segments. Amid these shifts, regulatory frameworks and payer considerations continue to influence technology adoption and clinical trial design, underscoring the need for strategic alignment among innovators, clinicians, and policymakers.

How converging technological advances, patient-centered care models, and diagnostics-driven pathways are reshaping clinical practice and commercial strategy in male infertility

The landscape of male infertility care is undergoing transformative shifts driven by technological maturation, changing patient expectations, and a convergence of diagnostics and therapeutics. Precision diagnostics, including more accessible genetic testing and high-resolution semen analysis, are redefining diagnostic pathways and enabling tailored interventions. Simultaneously, the refinement of assisted reproductive procedures, such as intracytoplasmic sperm injection and targeted sperm retrieval techniques, has expanded options for couples where male factor issues are prominent.

Concurrently, non-conventional pathways are gaining traction: lifestyle and alternative therapies such as acupuncture, nutritional optimization, and structured weight management are increasingly integrated into preconception care plans. These shifts reflect broader health system priorities that favor holistic, patient-centered models and preventive strategies. On the commercial side, device miniaturization, improvements in laboratory automation, and the adoption of digital tools for remote monitoring have lowered barriers to scaling services, prompting new entrants and strategic partnerships. Taken together, these dynamics are reshaping clinical decision-making and accelerating the translation of research into practice.

Evaluating the cumulative operational and supply chain consequences of United States tariffs introduced in 2025 on devices, diagnostics, and therapeutic distribution within reproductive health

The introduction and implementation of tariffs in the United States in 2025 have introduced measurable friction into global supply chains that support reproductive health technologies, affecting manufacturers, distributors, and clinical service providers. Increased import costs for specialized equipment such as centrifuges, incubators, and precision microscopes can raise procurement complexity for laboratories and clinics, encouraging some providers to reassess supplier relationships and inventory strategies. In response, manufacturers and distributors have explored options including local assembly, diversified sourcing, and pricing adjustments to preserve access to essential instrumentation.

Beyond devices, tariffs can influence the availability and cost structure of diagnostics consumables and reagents used in genetic testing, hormone assays, and semen analysis. Those pressures have incentivized laboratory networks to optimize procurement cycles, invest in technical validation for alternative suppliers, and accelerate adoption of more efficient workflows that reduce per-test consumable use. Meanwhile, biopharmaceuticals and supplements that cross borders face shifted economics that may affect distribution channel strategies, with some vendors prioritizing direct sales or regional partnerships to mitigate tariff exposure. As a result, stakeholders are balancing near-term operational responses with longer-term strategic moves to shore up resilience against ongoing trade policy volatility.

Segment-focused insights linking treatment modalities, product typologies, clinical end users, and distribution strategies to prioritize development and commercialization pathways

Segment-level dynamics in male infertility reveal differentiated value drivers that inform product development and go-to-market strategies across treatment modalities, product types, end users, and distribution pathways. Based on treatment type, the landscape spans assisted reproductive technology, lifestyle and alternative therapies, medical therapy, and surgical procedures; assisted reproductive technology itself encompasses ICSI, IUI, and IVF, while lifestyle and alternative therapies include acupuncture, nutritional supplementation, and weight management, medical therapy incorporates antibiotic therapy, antioxidant therapy, and hormonal therapy, and surgical procedures comprise testicular sperm extraction, varicocelectomy, and vasovasostomy. Each of these treatment areas presents distinct clinical workflows, reimbursement considerations, and evidence generation needs that influence adoption timelines.

Based on product type, innovation and commercialization strategies must address devices, diagnostics, drugs, and supplements; within devices, the focus includes centrifuges, incubators, and microscopes, diagnostics cover genetic testing, hormone level testing, and semen analysis, drugs consist of antibiotic, antioxidant, and hormone classes, and supplements traverse amino acids, herbal extracts, and vitamins. Product design, regulatory pathways, and lab integration requirements differ markedly between capital equipment and point-of-care diagnostics, creating varied barriers to entry and collaboration opportunities. Based on end user, the market is served by diagnostic centers, fertility clinics, hospitals, and research institutes, each with unique procurement cycles, clinical expertise, and data integration needs. Based on distribution channel, organizations deploy direct sales, hospital pharmacies, online pharmacies, and retail pharmacies, and channel strategy influences margin structures, access to prescribers, and patient reach. Together, these intersecting segmentation lenses highlight where clinical demand, regulatory clarity, and commercial feasibility align to create priority opportunities for investment and partnership.

Regional dynamics and regulatory complexities across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape adoption, manufacturing, and partnership strategies

Regional dynamics exert considerable influence on clinical practice standards, regulatory expectations, and commercial pathways for male infertility products and services. In the Americas, clinical adoption trends and reimbursement structures favor integrated fertility services that combine diagnostics with assisted reproductive technologies; this environment supports investments in advanced laboratory instrumentation and comprehensive clinic-level service models. Meanwhile, regulatory harmonization efforts in the region shape cross-border supplier strategies and create opportunities for suppliers that can demonstrate robust clinical and quality data.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable healthcare funding models create a mosaic of adoption rates and clinical practices. Some European markets emphasize stringent diagnostic protocols and outcome reporting, whereas certain markets in the Middle East and Africa prioritize rapid capacity development and public-private partnerships to expand access. Across these jurisdictions, local manufacturing capacity and collaborative training programs influence procurement decisions. In Asia-Pacific, demographic shifts, rising awareness of fertility health, and expanding private healthcare sectors drive demand for both high-throughput diagnostics and point-of-care solutions. Rapidly developing clinical infrastructure and strong domestic manufacturing ecosystems encourage regionally tailored product designs and strategic alliances that accelerate commercialization timelines.

Competitive landscape analysis revealing how incumbents, specialized innovators, and strategic partnerships are driving differentiation and clinical adoption in male infertility

Competitive activity in male infertility spans long-established medical device and diagnostics firms, niche biotechnology innovators, clinically focused service providers, and emerging digital health entrants. Incumbent device and diagnostics companies emphasize reliability, regulatory compliance, and integration with laboratory information systems, whereas newer entrants frequently focus on automation, cost-efficiency, and digital analytics to differentiate their offerings. Strategic partnerships between clinical networks and technology developers are increasingly common, enabling co-development of validation studies and real-world evidence that support market access and clinician adoption.

At the same time, companies that combine diagnostic capabilities with therapeutic or service offerings gain advantages in end-to-end solutions, driving consolidation in certain segments. Smaller specialized firms often target unmet clinical needs with focused technologies such as advanced sperm selection, non-invasive genetic assays, or minimally invasive retrieval tools, and they frequently rely on licensing or strategic distribution agreements with larger players to scale. Across the competitive landscape, investment in clinical evidence, regulatory strategy, and post-market surveillance remains central to sustaining differentiation and supporting long-term adoption among clinicians and patients.

Actionable recommendations for industry leaders to align clinical evidence, supply chain resilience, patient-centered services, and channel strategies for durable competitive advantage

Industry leaders must pursue prioritized actions that align clinical utility with commercial viability and supply chain resilience. First, strengthening evidence generation through targeted clinical studies and real-world data initiatives will accelerate clinician confidence in new diagnostics and therapeutics and enable clearer value communication to payers and procurement bodies. Second, diversifying supply chains and considering regional manufacturing or assembly partnerships can mitigate exposure to trade policy shifts and ensure continuity of access to critical devices and consumables. These operational moves should be paired with investments in quality systems and regulatory readiness to speed market entry.

Third, organizations should adopt patient-centered service models that integrate lifestyle interventions, diagnostic precision, and coordinated referral pathways between diagnostic centers, fertility clinics, hospitals, and research institutes. Fourth, channel strategies must adapt: leveraging direct sales for institutional accounts while optimizing online and pharmacy partnerships to broaden patient access will balance reach with margin considerations. Finally, cultivating strategic alliances-whether through co-development, licensing, or clinical collaborations-will accelerate innovation, reduce time to validation, and distribute commercialization risk across complementary capabilities.

A rigorous multi-source research methodology combining clinical validation, regulatory review, and stakeholder interviews to ensure robust insights into male infertility care and commercialization

This research synthesis applied a multi-source, evidence-based methodology combining peer-reviewed literature, regulatory documentation, clinical guidelines, and primary interviews with clinicians, laboratory directors, and industry executives. The approach prioritized triangulation of quantitative laboratory performance data with qualitative insights on clinical decision-making, procurement behavior, and regulatory interpretation. Validation steps included cross-referencing device specifications with regulatory approvals, and corroborating clinical workflows with practicing specialists across diagnostic centers, fertility clinics, hospitals, and academic research institutes.

In addition, product-level analysis incorporated technical assessments of devices such as centrifuges, incubators, and microscopes, and evaluated diagnostic modalities including genetic testing, hormone level testing, and semen analysis against accepted clinical performance metrics. For therapeutic and supplement categories, the methodology emphasized mechanistic plausibility and clinical trial evidence where available, while recognizing the variable regulatory pathways that differentiate drugs, supplements, and complementary therapies. The research also examined distribution channel dynamics through interviews with procurement managers and channel partners, enabling a practical view of adoption barriers and facilitators across direct sales, hospital pharmacies, online pharmacies, and retail pharmacies.

Concise conclusion synthesizing clinical progress, operational challenges, and strategic priorities to guide stakeholders in transforming male infertility care delivery and commercialization

Male infertility represents a complex, evolving domain where clinical innovation, diagnostics advancement, and shifting commercial dynamics intersect. Progress in genetic and endocrine testing, refinements in assisted reproductive techniques, and growing emphasis on integrated care pathways have improved diagnostic clarity and expanded therapeutic choices. At the same time, operational pressures such as supply chain disruptions and evolving trade policy underscore the importance of resilient procurement strategies and regionalized commercialization plans.

Looking ahead, organizations that prioritize evidence-based innovation, form strategic partnerships across the value chain, and adapt distribution strategies to local realities will be best positioned to translate scientific progress into improved patient outcomes. By focusing on the alignment of clinical utility, regulatory compliance, and pragmatic channel execution, stakeholders can navigate the complexities of the landscape and help ensure that advances in male infertility care reach clinicians and patients efficiently and equitably.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advances in gene therapy targeting Y-chromosome microdeletions for male fertility optimization
  • 5.2. Surge in research on oxidative stress biomarkers guiding personalized antioxidant therapies in male infertility management
  • 5.3. Growing utilization of AI-driven semen analysis platforms for enhanced diagnostic accuracy in andrology labs
  • 5.4. Expansion of telemedicine-based fertility counseling services addressing male reproductive health access gaps
  • 5.5. Developments in 3D testicular organoids as predictive models for novel drug screening in male fertility research
  • 5.6. Increasing investment in non-hormonal male contraceptives influencing research in testicular function modulation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Male Infertility Market, by Treatment Type

  • 8.1. Assisted Reproductive Technology
    • 8.1.1. ICSI
    • 8.1.2. IUI
    • 8.1.3. IVF
  • 8.2. Lifestyle And Alternative Therapies
    • 8.2.1. Acupuncture
    • 8.2.2. Nutritional Supplementation
    • 8.2.3. Weight Management
  • 8.3. Medical Therapy
    • 8.3.1. Antibiotic Therapy
    • 8.3.2. Antioxidant Therapy
    • 8.3.3. Hormonal Therapy
  • 8.4. Surgical Procedures
    • 8.4.1. Testicular Sperm Extraction
    • 8.4.2. Varicocelectomy
    • 8.4.3. Vasovasostomy

9. Male Infertility Market, by Product Type

  • 9.1. Devices
    • 9.1.1. Centrifuges
    • 9.1.2. Incubators
    • 9.1.3. Microscopes
  • 9.2. Diagnostics
    • 9.2.1. Genetic Testing
    • 9.2.2. Hormone Level Testing
    • 9.2.3. Semen Analysis
  • 9.3. Drugs
    • 9.3.1. Antibiotics
    • 9.3.2. Antioxidants
    • 9.3.3. Hormones
  • 9.4. Supplements
    • 9.4.1. Amino Acids
    • 9.4.2. Herbal Extracts
    • 9.4.3. Vitamins

10. Male Infertility Market, by End User

  • 10.1. Diagnostic Centers
  • 10.2. Fertility Clinics
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Male Infertility Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Male Infertility Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Male Infertility Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Male Infertility Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Ferring Arzneimittel AG
    • 15.3.2. Merck KGaA
    • 15.3.3. Bayer AG
    • 15.3.4. Sun Pharmaceutical Industries Ltd
    • 15.3.5. Endo International plc
    • 15.3.6. Roche Diagnostics International AG
    • 15.3.7. Thermo Fisher Scientific Inc
    • 15.3.8. Cook Medical LLC
    • 15.3.9. Hamilton Thorne Ltd
    • 15.3.10. Vitrolife AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL MALE INFERTILITY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS MALE INFERTILITY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA MALE INFERTILITY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL MALE INFERTILITY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. MALE INFERTILITY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. MALE INFERTILITY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MALE INFERTILITY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MALE INFERTILITY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MALE INFERTILITY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MALE INFERTILITY MARKET SIZE, BY ICSI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MALE INFERTILITY MARKET SIZE, BY IUI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MALE INFERTILITY MARKET SIZE, BY IVF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MALE INFERTILITY MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MALE INFERTILITY MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MALE INFERTILITY MARKET SIZE, BY WEIGHT MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MALE INFERTILITY MARKET SIZE, BY TESTICULAR SPERM EXTRACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MALE INFERTILITY MARKET SIZE, BY VARICOCELECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MALE INFERTILITY MARKET SIZE, BY VASOVASOSTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MALE INFERTILITY MARKET SIZE, BY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MALE INFERTILITY MARKET SIZE, BY CENTRIFUGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MALE INFERTILITY MARKET SIZE, BY INCUBATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MALE INFERTILITY MARKET SIZE, BY MICROSCOPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MALE INFERTILITY MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONE LEVEL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MALE INFERTILITY MARKET SIZE, BY SEMEN ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MALE INFERTILITY MARKET SIZE, BY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MALE INFERTILITY MARKET SIZE, BY ANTIOXIDANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MALE INFERTILITY MARKET SIZE, BY HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MALE INFERTILITY MARKET SIZE, BY AMINO ACIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MALE INFERTILITY MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MALE INFERTILITY MARKET SIZE, BY VITAMINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MALE INFERTILITY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MALE INFERTILITY MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MALE INFERTILITY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MALE INFERTILITY MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL MALE INFERTILITY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL MALE INFERTILITY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL MALE INFERTILITY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL MALE INFERTILITY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS MALE INFERTILITY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS MALE INFERTILITY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS MALE INFERTILITY MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS MALE INFERTILITY MARKET SIZE, BY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS MALE INFERTILITY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY LIFESTYLE AND ALTERNATIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY MEDICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA MALE INFERTILITY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA MALE INFERTILITY MARKET SIZE, BY ASSISTED REPRODUCTIVE TEC